Watercress Research reaches £4.2m valuation following new funding round

Developing urease inhibitory products from watercress plants has seen Exeter-based Watercress Research Ltd secure an estimated £531.2k in new funding. These phytochemical-based applications are intended for use in continence care, cosmetics, and the food and drink sectors. The company also produces its own brand of skincare, including a barrier cream for problem skin sold to consumers and through pharmacy chains.

The business was incorporated in 2019 and currently lists six employees in its latest financial filings, while LinkedIn records a headcount of four. For the year ending 31 December 2024, the firm reported a loss of £179.5k. This new round brings the post-money valuation to approximately £4.2m.

This funding follows £408.4k raised by the company during 2025. Documentation for the current share issue was filed in August, following an allotment of shares that took place in June.